To include your compound in the COVID-19 Resource Center, submit it here.

Bezlotoxumab: Phase III data

The double-blind, international Phase III MODIFY II trial in 1,203 patients receiving standard of care (SOC) antibiotics for CDI showed that a single IV infusion of 10 mg/kg bezlotoxumab alone and in

Read the full 320 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE